Andrzej Semczuk

List of Publications by Year
in descending order

53	836	516215 16	525886 27
papers	citations	h-index	g-index

54	54	54	1265
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Retrospective Comparison of Laparoscopic versus Open Radical Hysterectomy for Early-Stage Cervical Cancer in a Single Tertiary Care Institution from Lithuania between 2009 and 2019. Medicina (Lithuania), 2022, 58, 553.	0.8	2
2	Antioxidative, Anti-Inflammatory, Anti-Obesogenic, and Antidiabetic Properties of Tea Polyphenolsâ€"The Positive Impact of Regular Tea Consumption as an Element of Prophylaxis and Pharmacotherapy Support in Endometrial Cancer. International Journal of Molecular Sciences, 2022, 23, 6703.	1.8	16
3	Failure of multiple surgical procedures and adjuvant chemotherapy in early-stage steroid-cell ovarian tumor treatment: a case report and literature review. Journal of International Medical Research, 2021, 49, 030006052098319.	0.4	6
4	Uterovesical fistula caused by cervical pessary placed for the prevention of preterm delivery â€“ case report. Journal of Gynecology Obstetrics and Human Reproduction, 2021, 50, 102047.	0.6	0
5	Fertility-Sparing Methods in Adolescents Affected by Endometrial Cancer: A Comprehensive Review. Journal of Clinical Medicine, 2021, 10, 1020.	1.0	3
6	Ovarian adult-type granulosa cell tumor concomitant with simple endometrial hyperplasia: a case study with selected immunohistochemistry. Journal of International Medical Research, 2020, 48, 030006051988698.	0.4	4
7	An association of iNKT+/CD3+/CD161+ lymphocytes in ovarian cancer tissue with CA125 serum concentration. Immunobiology, 2020, 225, 152010.	0.8	3
8	Betaglycan Gene (TGFBR3) Polymorphism Is Associated with Increased Risk of Endometrial Cancer. Journal of Clinical Medicine, 2020, 9, 3082.	1.0	4
9	Paternal age is affected by genetic abnormalities, perinatal complications and mental health of the offspring (Review). Biomedical Reports, 2020, 12, 83-88.	0.9	11
10	Immunohistochemical results and case report of an incidental finding of uterine polypoid adenomyoma after long-time therapy for metrorrhagia. Pathology Research and Practice, 2020, 216, 152998.	1.0	1
11	Ovarian endometrioma â€“ a possible finding in adolescent girls and young women: a mini-review. Journal of Ovarian Research, 2019, 12, 104.	1.3	19
12	Prediction of 10-year Overall Survival in Patients with Operable Cervical Cancer using a Probabilistic Neural Network. Journal of Cancer, 2019, 10, 4189-4195.	1.2	7
13	Atypical Endometrial Hyperplasia Arising in a Cesarean Section Scar: A Mechanism of Malignant Transformation. Case Reports in Oncology, 2019, 12, 317-321.	0.3	1
14	Blebbistatin reveals beneficial effects on the cystometric parameters in an animal model of detrusor overactivity. Naunyn-Schmiedeberg's Archives of Pharmacology, 2019, 392, 843-850.	1.4	2
15	Breast cancer in an 18-year-old female: A fatal case report and literature review. Cancer Biology and Therapy, 2018, 19, 543-548.	1.5	4
16	Structural arrangement of vesicouterine fistula revisited: An immunohistochemical study documenting the presence of the endometrium. Journal of Obstetrics and Gynaecology Research, 2018, 44, 341-346.	0.6	2
17	An Unusual Coexistence of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma with Endometrioid-Type Endometrial Cancer in a 58-Year-Old Woman: A Case Study with Literature Review. Case Reports in Oncology, 2018, 11, 347-352.	0.3	4
18	Serum paraoxonase 1 activity and protein N-homocysteinylation in primary human endometrial cancer. Tumor Biology, 2018, 40, 101042831879786.	0.8	9

#	Article	IF	Citations
19	Inhibition of Rho kinase by GSK 269962 reverses both corticosterone-induced detrusor overactivity and depression-like behaviour in rats. European Journal of Pharmacology, 2018, 837, 127-136.	1.7	15
20	Congenital vesicouterine fistulasâ€"A PRISMAâ€compliant systematic review. Neurourology and Urodynamics, 2018, 37, 2361-2367.	0.8	1
21	Expression of p53 and selected proliferative markers (Ki-67, MCM3, PCNA, and topoisomerase IIÎ±) in borderline ovarian tumors: Correlation with clinicopathological features. Histology and Histopathology, 2018, 33, 171-179.	0.5	6
22	Prognostic Parameters for Patients with Cervical Cancer FIGO Stages IA2-IIB: A Long-Term Follow-Up. Oncology, 2017, 93, 106-114.	0.9	30
23	Assessment of Th17 lymphocytes and cytokine IL-17A in epithelial ovarian tumors. Oncology Reports, 2017, 37, 3107-3115.	1.2	10
24	The Putative Role of TP53 Alterations and p53 Expression in Borderline Ovarian Tumors - Correlation with Clinicopathological Features and Prognosis: A Mini-Review. Journal of Cancer, 2017, 8, 2684-2691.	1.2	6
25	Prediction of 5â€"year overall survival in cervical cancer patients treated with radical hysterectomy using computational intelligence methods. BMC Cancer, 2017, 17, 840.	1.1	44
26	Significance of TGFBR3 allelic loss in the deregulation of TGFÎ² signaling in primary human endometrial carcinomas. Oncology Reports, 2016, 35, 932-938.	1.2	5
27	Increased percentage of Th17 cells in peritoneal fluid is associated with severity of endometriosis. Journal of Reproductive Immunology, 2016, 117, 39-44.	0.8	70
28	Should we be more aware of endometrial cancer in adolescents?. Medycyna Wieku Rozwojowego, 2016, 20, 169-173.	0.2	1
29	Multiple recurrences of early-stage, endometrioid-type G2 endometrial cancer with a long-time follow-up: A case study. Pathology Research and Practice, 2015, 211, 478-480.	1.0	0
30	Surface antigen expression on peripheral blood monocytes in women with gynecologic malignancies. BMC Cancer, 2015, 15, 129.	1.1	9
31	Role of p53 Pathway Alterations in Uterine Carcinosarcomas (Malignant Mixed MÃ¼llerian Tumors). Oncology, 2014, 87, 193-204.	0.9	7
32	Expression of genes encoding extracellular matrix proteins: A macroarray study. Oncology Reports, 2014, 32, 2349-2353.	1.2	7
33	T regulatory lymphocytes in patients with endometriosis. Molecular Medicine Reports, 2014, 10, 1072-1076.	1.1	34
34	Coexistence of homologous-type cervical carcinosarcoma with endometrioid-type G1 endometrial cancer: a case report with an immunohistochemical study. International Journal of Clinical and Experimental Pathology, 2014, 7, 7191-5.	0.5	6
35	GPER-1 Expression Decreases During Breast Cancer Tumorigenesis. Cancer Investigation, 2013, 31, 309-315.	0.6	41
36	TGFÎ²-pathway is down-regulated in a uterine carcinosarcoma: A case study. Pathology Research and Practice, 2013, 209, 740-744.	1.0	5

#	Article	IF	Citations
37	Physiology and pathology of the mammary gland in women in different periods of life (menopausal) Tj ETQq1 1 0.784314 rgBT /Overl	0.6	0
38	p53 is not related to Ki-67 immunostaining in the epithelial and mesenchymal components of female genital tract carcinosarcomas. Oncology Reports, 2013, 30, 1661-1668.	1.2	2
39	G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer. Breast Cancer Research and Treatment, 2011, 128, 457-466.	1.1	144
40	Expression of Endoglin in Primary Endometrial Cancer. Oncology, 2011, 81, 243-250.	0.9	9
41	Dysregulation of Betaglycan Expression in Primary Human Endometrial Carcinomas. Cancer Investigation, 2011, 29, 137-144.	0.6	9
42	The Pattern of p14ARF Expression in Primary and Metastatic Human Endometrial Carcinomas. International Journal of Gynecological Cancer, 2010, 20, 993-999.	1.2	5
43	Role of GPR30 in endometrial pathology after tamoxifen for breast cancer. American Journal of Obstetrics and Gynecology, 2010, 203, 595.e9-595.e16.	0.7	33
44	Prevalence of Allelic Loss at <i>TP53</i> in Endometrial Carcinomas. Oncology, 2010, 78, 220-228.	0.9	12
45	Common mitochondrial polymorphisms as risk factor for endometrial cancer. International Archive of Medicine, 2009, 2, 33.	1.2	23
46	Immunohistochemical analysis of carcinomatous and sarcomatous components in the uterine carcinosarcoma: A case report. Pathology Research and Practice, 2008, 204, 203-207.	1.0	14
47	P16 alterations increase the metastatic potential of endometrial carcinoma. Gynecologic Oncology, 2008, 111, 365-371.	0.6	35
48	P53/MDM2 overexpression in metastatic endometrial cancer: correlation with clinicopathological features and patient outcome. Clinical and Experimental Metastasis, 2007, 24, 503-511.	1.7	20
49	Allelic Loss at TP53 Is Not Related to p53 Protein Overexpression in Primary Human Endometrial Carcinomas. Oncology, 2005, 69, 317-325.	0.9	16
50	TGF-Î² signaling is disrupted in endometrioid-type endometrial carcinomas. Gynecologic Oncology, 2004, 95, 173-180.	0.6	44
51	Expression of TGF-Î² type I and II receptors in normal and cancerous human endometrium. Cancer Letters, 2002, 186, 231-239.	3.2	37
52	Immunohistochemical analysis of MIB-1 proliferative activity in human endometrial cancer. Correlation with clinicopathological parameters, patient outcome, retinoblastoma immunoreactivity and K-ras codon 12 point mutations. The Histochemical Journal, 2001, 33, 193-200.	0.6	21
53	p53 protein detection by the Western blotting technique in normal and neoplastic specimens of human endometrium. Cancer Letters, 2000, 148, 197-205.	3.2	15